Summit Therapeutics Share Discussion Threads

[waterloo01] 01/2/2017 19:30

Chris, no idea. Tomorrow, on ETZ results, before I get a bus pass? Just think we are a R&D company focused mainly on DMD but also with RDZ and neither have the desire nor skill set to run a consumer facing pharma. The different teams would 'slot in' and the big cheeses enjoy some stunning sunsets! All IMO.

[chrisatrdg] 01/2/2017 19:18

Hi waterloo01 Follow your sound logic & would ask based on the current published Summit timetable at which point do you think we will cease being a 'independent company'.

PS Agree with your Trump comments - scary moments.

[waterloo01] 01/2/2017 18:21

Shame the rise didn't hold on AIM but looking healthy on Nasdaq with half decent volume. It wouldn't surprise me if a number of traders switch from SRPT to SUMMT. Exondys 51 is still only applicable to 13%, less if insurance doesn't cover) compared to the potential with ETZ. I also feel that whatever you think of Trump (and my head slumps on the table whenever I do) IF he does what he says he wants to re FDA, I see no reason that we couldn't get conditional approval, on both our drugs, much sooner.

Both drugs have very good safety profiles and both offer hope to patients, who in both cases without access to drugs like ours are living a death sentence (and in short order with C.diff).

If that's not as close to being what Trump (head slump) has suggested as the way forward, I don't know what is.

Edit: If either of the above happens, I'd very much doubt we would remain an independent company and I'm fairly confident that that, is the end game here.

[luminoso] 01/2/2017 18:07

Hyper. I think you'll find its profit first with all the Big Pharma boys. Whatever they pay us, if they buy us out, they will go on to make enormous profits from the drug. There would be no other reason for buying us out for them and Trump will pave the way for them to do so, no doubt. I am under no illusions that eventually I will be taking pretty dirty money for my shares here. It's the nature of the beast IMO.

[cautiousmoney] 01/2/2017 16:48

and we treat 100% of the lads, can only see large ii buying here and a good multibagging prior to a look from a huge pharma, I will take £10 a share in cash and a one for one in shares from Pfizer or GSK ;-)

[hugus maximus] 01/2/2017 16:37

cautiousmoney .. but there's a promise of no dilution (Welcome Trust / Bill Gates / UK health fund?)

By the time this all starts to come to fruition (unless RNS was some legality in anticipation of "the deal" announcement?) .. there may well be a different FDA regime as Trump promised new drugs being given less expensive, quicker access to market etc.

Whatever - today's RNS is a statement of good intent .. and as such is as you say "good news".

[cautiousmoney] 01/2/2017 16:28

700 in phase 3 that's not going to be cheap.

still good news though

:-))))

[abergele] 01/2/2017 16:08

Good,and old budy Andy Laws from them days has some still I believe.
Have to admit selling out ,been here a while,,this is what (Mick)Andy Laws has said,getting stuck in the beggars and taking up all the best of the days weather etc..
I will meet him in Malta tomoz ,he's been there 2 weeks,and we shall have 2 weeks bumping into oneanother again no doubt..take care Al.

[abergele] 01/2/2017 15:56

luminoso,
I agree,but they won't make but a ton if this turns quickly with the spreads,and if a buyer is lurking,thinking this is cheap as it comes now...gla

Hello again to you H Al.how goes it up there in Ed>>>>>h

[luminoso] 01/2/2017 15:29

Having held my core holding in Summit several years now, I actually wonder who is the more silly, me or the traders who have taken their 10 percent over and over again in the same period ! It takes all sorts to make a market and I guess we can live and let live.

[abergele] 01/2/2017 13:41

Freedosh,
If only they could see that keeping above the dma's this has legs and legs if they wanted to trade,most traders clear off and find another share to ruin afterwards.
imho

[waterloo01] 01/2/2017 13:38

Lucky had a very small top up yesterday, rather well timed (just 1500 shares but all helps).

Good reaction which I expect is due to the distinct reference to partnership/grants not funding (which was always a concern). I also wonder if the 2018 start is partly to see what the FDA get up to post Trump.?

[freedosh] 01/2/2017 13:33

PS. Do we have a new cup and handle in the making?

[abergele] 01/2/2017 13:12

Silly beggars selling it at the first opportunity,
there's more to come here,it's only just starting to unfold..omho..gla lth's

[maurillac] 01/2/2017 13:04

certainly is ! good day for holders and many more to come i hope !
m

[anusol] 01/2/2017 12:59

damn quiet on here given the 22% increase in share price that's just taken place in the last hour.

[hugus maximus] 01/2/2017 12:23

Great news ... non dilutive funds from Welcome again (?) ... and perhaps organisations like Bill Gates?

Some nice share buying in reaction to the reminder that Summit's C Diff drug will be a great earner and confirmation here that the companies fortunes a not just reliant on DMD work.

[football] 01/2/2017 12:20

:) that's better



Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings

[waterloo01] 01/2/2017 12:04

Slower start than expected but confirmation it won't be funded by equity but partnership or grants. Trial size isn't overly onerous.

[euroto] 01/2/2017 11:39

Many thanks HM

[hugus maximus] 01/2/2017 10:44

euroto - apologies - I really don't see the possibility of Sarepta defaulting on their involvement with Summit as the least bit negative.

They came along like knights in shining armour with $40 million that changed Summit's fortunes in exchange for future european rights to SMTC1100.(and undoubtedly a further $20 million will be in Summit's account in the not too distant future) However I would be concerned if Summit were to be totally reliant on Sarepta's very controversial eteplirsen success, which may still turn up "issues" in further data studies.

What I was suggesting (sorry - not very eloquently) was that if Sarepta doesn't turn things around, any default in the Summit deal would simply open the door to other more solid suitors. I was attempting to say that what ever the future holds for Sarepta, any problems they have, should by the coming autumn, not affect Summit.

EDIT - just read my previous note back and you were right in suggesting it did sound gloomy. My feelings about the current scenario are anything but! Best HM